Direct delivery ofmedication to the sinuses with standa rd neb ulizers is difficult to achieve. The nasal inhalation of aerosolized med ications is dep endent on the size of the particles and the p ressure with which they are delive red; when the pa rticles are too sma ll or the p ress ure is too low, the drug canno t reach the sinus es. The ab ility of top ical medications to treat sinus disorders can be imp roved if the medication co uld be deli vered di rectly to the sinuses .
Introduction
The abi lity to deli ver medications directly into the sinuses co uld reduce the need for system ic medications and their possible untoward eve nts. Direct de livery might also impr ove the effective ness of tradi tional topi cal medica-tions and lessen the severi ty of a wide variety of sinusrelated symp toms and diseases.
The ability of nebu lizers to de liver medications to the paranasal sinuses ca n be limited by insufficient particle size and low aerosol pressure.I Sufficient particle size is essential to ass ure dep osition in the sinuses,' and the speed with which the particles are delivered can determine how far through the sinuses they spread.' Particl es smaller than 5 11m are likely to be dep osited in the lower airways . Depositi on into the sinuses is best achieved when the aerosolized particl es are 16 to 25 11m in size and when the pressure gradient is sufficient according to Lapl ace' s law. ' In a study of functi onal endoscopic sinus surgery combined with an initial topical antimicro bial treatment course and serial long-term monthl y sinus antimicrobial lavage, Moss and King dem onstrated a redu ction in repe at sinus surgery in a popul ation of cystic fibros is patient s who had chro nic sinusitis. 5 Th e success of that regim en in reliev ing symp toms was appare nt both from patient reports and from excellent co mp liance with the lavage maintenance prog ram by most patients. The resea rchers co ncl uded, "It seem s possible that the ESSAL [endosco pic surgery with serial antimicro bia l lavage] program may be applicable to other disea se states pred isposed to chro nic refr actory infectious sinusitis." Ne vert heless, ESS AL still invo lves surgery, which could be avo ided if nasal lavage could allev iate symptoms on its own.
The purpose of this study was to ge nera te pilot data fro m which sample size calculations could be made for larger random ized trials. Our study was designed to determ ine whether aero solized techn etium Tc 99m-labeled normal saline could be depo sited into the paranas al Come see us at AAO ·HNS Booth #500 , 502, and 504
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Materials and methods
Device. The Rin oFlow Nasal Wa sh and Sinus System (Res pironics, Inc.; Cedar Grove, N.J .) consists of a portable, sealed, electric (l 15 or 230 V), lubric ant-free, piston compressor and a micro nizer cha mber (figure I).
The chamber is co nnected to the co mpress or by flex ible PVC tubin g and is made of polycarb onate clear plastic that can be sterilized by boiling. The microni zer chamb er is made up of fou r parts: an outer shell, an inner cha mber, a baffle, and the bod y.
The RinoFlow system generates particles between 20 and 30 urn in size. Th e device can deliver the particles at two different rates: 8 Umin with turbul ent flow (pos ition I) and 4 Umin with lamin ar flow (position 2). The rate is controll ed by adj usting the position of. the outer shell (figure 2). In position I, a space is formed between the inner and outer shells where mucosecretions can be caught. The delivery pressure of the micronized wash solution prevents the nasal drainage from entering the inner chamber and mixing with the nebuli zing solution. A maximum of 40 em (± 6 em) of water pressure can be delivered to the upper airway at a rate of 8 Umin. In position 2, the gap is closed and the lam inar jet reaches the paran asal os at a rate 552 of 4 U min. To enha nce delivery to the paranasal os, patients are instruct ed to periodically close the opposite nostril, to keep their mouth closed, and to swallow while holdin g their breath . Th is maneuver creates a pressure gradient in the upper airway wherein the pressure in the nasal cavity will be greater than the pressure in the sinuses. The difference in pressure will force the aerosol particles from the high-pressure area (the nasal cav ity) toward the low-p ressure area (the sinuses) until the pressures equalize.
Subjects. Subjects rec ruited for the trial were healthy men and women, age d 18 to 40. Women who were pregnant, nursing, or of childbearing potential were excluded. Other excl usion criteria were the presence of mod erate to severe septal deviation; a history of seasonal allergies, nasal polyp s, or sinusitis; the presence of cys tic fibrosis; a history of ciga rette smoking; recent use of any drug (presc ription, ove r-the-counter, or ille gal); and abnorm al computed tomography (CT) result s.
All subjects who initi ally qualified for the trial after telephone scree ning were scheduled for an ENT exa mination by an otolaryngologist. Follo win g the ENT history and physical exam , subjects who were still elig ible were scheduled for CT of the sinuses. A norm al CT scan was required for participation in the study.
A total of 15 subje cts passed the history and physical ex am portion of the screenin g and unde rwent CT . Only five of these subjec ts had a norm al CT res ult, and they we re included in the final techn etium trial, The subjects, all men, were aged 21 to 32 (mea n: 27 .2; SD: ± 4.92).
Methods. On the day of their intervention, the five subjects reported to the nucle ar imagin g laborat ory at the Uni versity of Pitt sburgh Medical Cent er-Passavant Hospital, Initially, the subjects used the RinoFl ow device in position I to was h the nasal cav ity with a solution of buffered 0.9% norm al saline. Both nostril s were was hed. Subjects were then iso lated in a radiation-safe room to proceed with the techn etium Tc 99m trial. Th e techn etium solution was compounded under strict nucl ear gu idelin es and placed in the nebu lizin g chamber. Subj ects nebuli zed the technetium into their nasal cav ity with the RinoFlow in position 2. During nebuli zation of the techn etium, subjec ts were aske d to voluntarily occlude the untr eated nostril and swa llow . Thi s "pinch and swa llow" maneuver is similar to the Val salv a' s maneu ver to open blocked eustachian tubes dur ing airplane decent ; it is also called Politzer 's method to force increased pressure throu gh small openings.
Following treatm ent of the nasal cav ity with the technetium, subjec ts were asked to swa llow a small amount of water to flush any excess technetium from the posterior oronasa l pharynx. Four radioac tive mark ers were placed on bony landmarks of the face , and a lead drap e was placed over the nose to reduce the amo unt of excessive The OPMI TwinER Optical Drill " is the most significant breakth rough in ENT surgery si nce Zeiss introduced the first ENT microscope in 1953. Zeiss has created the world'sfirst mi croscope with an integrated Er:YAG laser. TheOptical Drill ""isa highly efficient,non-contact, cutting and boringtool (tissueablation) that is based on light.
TheOPMI TwinER significantlyreducesthe risk of structural damage and post-surgical complications resulting from vibration associated with mecha nical drilling methods. The Er:YAG laser tech nology coupled with the Zeiss microscope makes the OPM I TwinER Optical Drill" the ENT product that is ra ising the standard of ca re for surgery of the middle ear.
Th e OPMI TwinER's compact design also makes it an excel lent microscope for trad itional mi crosurgical procedures where a laser is not required . Of course the Carl Zeiss, Inc. 
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Discussion
Thi s trial was designed as an obse rvational study to dete rmin e whether technetium could be nebul ized into the sinuses with the Rin oFlow Nasa l Wash and Sinu s System . Th e five subjects who met the criteria for inclusion were carefully screened, and none had nasal pathology. Radio acti vity was noted in the sinuses of three of the five subje cts. Th is study did not measure the actual amou nt of techn etium that reach ed the sinuses; the lack of quantification was a limit ation inherent in the study design. The use of an aerosol decongestant (oxymetazo Iine) by three of the subjects (subjects 2, 3, and 4) prior to technetium administrat ion had no apparent effect on sinus deposition. Th e other two subjects (subjects I and 5) did not ag ree to be retes ted with oxy metazo line, thu s we do not know if a single dose of the decon gestant would have cha nged the outco me in subj ect 5, who did not manifest any ev ide nce of sinus deposit ion . If our trial had included subjects who did have nasal pathology, we would have used a larger dose of nasal decon gestant with the goal of redu cin g any swelling of the nasal mucosa pr ior to the nebul izat ion of technetium. It is possible that a larger dose of nasal decongestant would have had a favo rable impact on the result s of this study. Th e best result s might be obtained by first administering a nasal wash in the positi on I setting, then a top ical decon gestant, and finally nebul ization of the drug with the RinoFlo w device set to positi on 2.
During this study, significa nt gamma activity within the nasal cavity and nasoph arynx completely ob scur ed the regions of the sphenoid and ethmoid sinuses, thu s acti vity in the nasal cavity that reached the ga mma camera detectors. A nuclear scan of the head and neck was then performed to determine whether any technetium had reach ed the paran asal sinus ca vities. Three of the five subjects underwent a seco nd test that was similar to the first exc ept that they recei ved a single pretreatment nasal spray do se of the deconge stant oxymetazoline Hel 0.05 % prior to the technetium trial. It was hypothesized that opening the sinus passages would allow for better depo sition.
Results
The result s of the techn etium trial are shown in the table. Subjects 1 and 5 were eva luated only once , without the oxymetazoline decon gestant. Subject I showed ev idence of paranasal sinus technetium dep osition , and subje ct 5 did not. Subjects 2, 3, and 4 were evaluated with and without oxymetazoline. Subject 2 exhibit ed no ev ide nce of paranasal sinus deposition with or without the dec onges-Pt. tant; subjects 3 and 4 did dem onstrate some evidence of sinu s dep osition both with and without oxymeta zolin e.
According to our findings, some degree of vent ilation was see n in 60 % of the subjects, althou gh deposition was incomplete and inconsistent. Moreover, the adm inistration of a single dose of dec onge stant did not imp rove the deposition of the technetium. limiting o ur evalua tio n o f the de g ree o f ve nt ila tio n. W e w ere aware ofthi limitati on beforehand. but we felt there was no so lutio n or alternative to overcome it. The use of iodinated radiographi c contra t material would have be en impractical becau e of it high vi co ity, th e 0 molarity of mo t o f the agent . and the potential for a se ve re allergic reaction. The u e of a co lo red vital dye would ha ve required an endo copic confirmation of ag ent deli ery to the parana al inu e . which we al 0 con idered to be impractical. Although Hyo et al ' reported that pretreatment of the na : al cavity with a deconge tant can improve depo ition to the s inus es . we did not find thi to be the case in our . tudy. Ho we ve r. the do age of decongestant we used was le ss than optimal.
Pa ali et al reported that la vage with the RinoFlow device re ulted in a reduction-and in ome ca e an elimination-of bacterial colonie on na sal wabs taken from patient who used the device to douche the na al cavity. ' However. they did not report on co t-effectivene s or long-term outcomes.
Our stud y provides initial pilot data on the u e of the R ino Flow asa l Was h and Sinus System as a drug delivery device. Its poten tia l application include the irrigation of paranasa l cavities following inu s s urge ry. the delivery of enzymatic medication to cy stic fibrosi patient. and the deli ery of mucolytic so lutio ns to dilute th e thick. tenacious ecretion that ome patient experience. In an acute inflammatory inu: di sea e. the delivery of even a mall amount of pharmaceutical agent might complement sy temic anti-inflammatory and antibiotic therapy.
Ba sed on the re sults of thi fea ibility stu d y. we conclude that the R ino F lo w asa l Wash and Sinus System can deliver ae ro sol directly to the inuse s in so me patient . Our work was intended to provide data from which larger. more generali zed stud ies co u ld be de igned. and our re su lt: ugge. t that further tudy is warranted.
